Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
LIFE HEALTHCARE GROUP HOLDINGS UNSPON ADR EA REPR 4 ORD ZAR0.00
LTGHY
5
Enerpac Tool
EPAC
US OptionsDetailed Quotes
SGMO250516P1500
- 0.80
- 0.000.00%
15min DelayClose May 2 16:00 ET
0.00High0.00Low
0.80Open0.80Pre Close0 Volume6.12K Open Interest1.50Strike Price0.00Turnover358.83%IV3.85%PremiumMay 16, 2025Expiry Date0.77Intrinsic Value100Multiplier14DDays to Expiry0.03Extrinsic Value100Contract SizeAmericanOptions Type-0.7523Delta0.6234Gamma0.88Leverage Ratio-0.0057Theta-0.0004Rho-0.66Eff Leverage0.0004Vega
Sangamo Therapeutics Stock Discussion
Sign in to post a comment
$Sangamo Therapeutics (SGMO.US)$
We are proud to be showcasing our latest pipeline advances at ASGCT, including three platform presentations, reflecting our mission to develop innovative neurology genomic medicines to treat debilitating neurological diseases,” said Sandy Macrae, Chief Executive Officer of Sangamo Therapeutics. “We are particularly excited to...
We are proud to be showcasing our latest pipeline advances at ASGCT, including three platform presentations, reflecting our mission to develop innovative neurology genomic medicines to treat debilitating neurological diseases,” said Sandy Macrae, Chief Executive Officer of Sangamo Therapeutics. “We are particularly excited to...
1
1
$Sangamo Therapeutics (SGMO.US)$ nice movement
$Sangamo Therapeutics (SGMO.US)$ trash going down shit no one intersted in this i think
1
2
$Sangamo Therapeutics (SGMO.US)$ something today
1
$Sangamo Therapeutics (SGMO.US)$ Fabry deal in Q2, these will blow it up
2
2
$Sangamo Therapeutics (SGMO.US)$
This licensing agreement materially strengthens Sangamo's financial position through a $18 million upfront payment that significantly bolsters their balance sheet. For context, this single payment represents approximately 14% of Sangamo's entire market capitalization ($128.6 million), making it an exceptionally material transaction.
The deal's structure is particularly advantageous for Sangamo, as it creates asymmetric upside with minimal ongoin...
This licensing agreement materially strengthens Sangamo's financial position through a $18 million upfront payment that significantly bolsters their balance sheet. For context, this single payment represents approximately 14% of Sangamo's entire market capitalization ($128.6 million), making it an exceptionally material transaction.
The deal's structure is particularly advantageous for Sangamo, as it creates asymmetric upside with minimal ongoin...
1
$Sangamo Therapeutics (SGMO.US)$
Sangamo's licensing deal with Eli Lilly represents a significant value-creation event for the company. The $18 million upfront payment is substantial for Sangamo, representing approximately 14% of their $128.6 million market capitalization. This non-dilutive funding provides immediate capital without shareholder dilution.
The agreement's structure is particularly favorable - Sangamo transfers technology but bears no further development c...
Sangamo's licensing deal with Eli Lilly represents a significant value-creation event for the company. The $18 million upfront payment is substantial for Sangamo, representing approximately 14% of their $128.6 million market capitalization. This non-dilutive funding provides immediate capital without shareholder dilution.
The agreement's structure is particularly favorable - Sangamo transfers technology but bears no further development c...
1
$Sangamo Therapeutics (SGMO.US)$ short too strong
$Sangamo Therapeutics (SGMO.US)$ the news is amazing waiting for the volume
2
No comment yet
Market Insights
Discussing
2025 Buffett shareholders' meeting: What's the new buzz in value investing?
🎙️Discussion 1. Do you think Buffett was scooping up stocks during the recent dip? 2. In the face of market changes, do you prefer to stick
Moomoo News Global
Apr 28 18:10
Warren Buffett Stands Tall as U.S. Stocks Tumble: How the 'Oracle' Is Tackling Tariff Impacts
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context,
Moo Live
Jan 23 16:54
MicroStrategy Q4 2024 earnings conference call
BigAlMoney :